Latest News

Date Title Topic
25 Nov 2015 FDA Approves Ixazomib, New Oral Proteasome Inhibitor for Treatment of Multiple Myeloma Haematologic malignancies - Anticancer agents & Biologic therapy
24 Nov 2015 FDA Approves Nivolumab for the Treatment of Advanced Renal Cell Cancer Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
24 Nov 2015 European Medicines Agency Recommends Granting a Marketing Authorisation for Asparaginase and Pegaspargase Haematologic malignancies - Anticancer agents & Biologic therapy
CME Tests for Handbooks
19 Nov 2015 FDA Approves Daratumumab for Patients With Previously Treated Multiple Myeloma Haematologic malignancies
18 Nov 2015 Dabrafenib Produces Rapid Shrinkage of Recurrent, BRAF-mutant Papillary Craniopharyngioma Personalised medicine - Endocrine cancers - Anticancer agents & Biologic therapy
17 Nov 2015 Distinct Evolutionary Trajectories Reported for Different Melanoma Subtypes Pathology/Molecular biology - Melanoma
16 Nov 2015 FDA Approves Osimertinib to Treat Patients With EGFR T790M Positive Advanced NSCLC After Progression to Other EGFR Tyrosine Kinase Inhibitors Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
12 Nov 2015 FDA Approves Cobimetinib as Part of Combination Treatment for Advanced Melanoma Melanoma - Anticancer agents & Biologic therapy
11 Nov 2015 Immunosurveillance in Breast Cancer Breast cancer - Cancer Immunology and Immunotherapy
10 Nov 2015 ESMO Preceptorship on Lung Cancer
10 Nov 2015 Pembrolizumab Receives FDA Breakthrough Therapy Designation in Advanced Colorectal Cancer Gastrointestinal cancers - Cancer Immunology and Immunotherapy
06 Nov 2015 European Medicines Agency’s Review Concludes Evidence Does Not Support That HPV Vaccines Cause Complex Regional Pain Syndrome and Postural Orthostatic Tachycardia Syndrome Epidemiology/Etiology/Cancer Prevention
05 Nov 2015 Patient-Derived Tumour Xenograft Models Encyclopedia Translational research
04 Nov 2015 FDA Approves Talimogene Laherparepvec for the Treatment of Melanoma Melanoma - Cancer Immunology and Immunotherapy